Prosecution Insights
Last updated: November 20, 2026

Dawanna Shar-Day White, USPTO Patent Examiner

Listed by the USPTO as WHITE, DAWANNA SHAR-DAY

Tech Center 1600 • Art Units: 1627 1629

This examiner grants 63% of resolved cases

Analysis

WHITE, DAWANNA SHAR-DAY is assigned to Tech Center 1600 and Art Unit 1627. Her profile records 130 resolved cases, a 63.1% allowance rate, a 21.1% interview lift, and a median of 1266 days to allowance.

The data supports a prosecution approach that combines substantive claim presentation with examiner engagement. The positive interview lift indicates that interviews may improve outcomes in appropriate cases, although the median timeline remains extended. The listed companies are BioTheryX Inc., Fujifilm Holdings Corporation, and Novartis AG. The listed firms are Jones Day, Juniv LLP, and McCarter & English, LLP.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

63.1%
Allow Rate
+3.1% vs TC avg
203
Total Applications
+21.1%
Interview Lift
1266
Avg Prosecution Days
Based on 130 resolved cases, 2023–2026

Rejection Statute Breakdown

3.6%
§101 Eligibility
13.9%
§102 Novelty
34.9%
§103 Obviousness
21.4%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18892564 COMPOUND AND PRODUCTION METHOD THEREOF, POLYMERIZABLE COMPOSITION, RESIN COMPOSITION, POLYMER, CURED SUBSTANCE, AND LAMINATE Non-Final OA FUJIFILM Corporation
18960021 NEW CRYSTALLINE FORMS OF SALT OF 7-CYCLOPENTYL-2-(5-PIPERAZIN-1-YL-PYRIDIN-2-YLAMINO)-7H-PYRROLO[2,3-D]PYRIMIDINE -6-CARBOXYLIC ACID DIMETHYLAMIDE Non-Final OA Novartis AG
18951962 GPR88-RECEPTOR-AGONIST Non-Final OA Boehringer Ingelheim International GmbH
18834350 IMIDAZOTETRAZINE COMPOUNDS AND TREATMENT OF TMZ-RESISTANT CANCERS Non-Final OA THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
18101772 COMPOUNDS AND METHODS FOR TREATING CANCER Non-Final OA Mayo Foundation for Medical Education and Research
18755002 ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER Non-Final OA VANDERBILT UNIVERSITY
18865738 CRYSTALLINE FORMS OF PICOLINAMIDE FUNGICIDE COMPOUND Non-Final OA CORTEVA AGRISCIENCE LLC
18548657 SUPPRESSION OF COVID-19 REPLICATION BY COVID-19 ENTRY INHIBITORS Non-Final OA THE CURATORS OF THE UNIVERSITY OF MISSOURI
18973967 METHODS AND COMPOSITIONS FOR DRUGS TO TREAT OPHTHALMIC DISEASES Non-Final OA Duke University
18857231 SMALL MOLECULE INDUCERS OF CARDIOMYOCYTES TO IMPROVE CARDIAC STRUCTURE AND FUNCTION Non-Final OA UNIVERSITY OF MARYLAND, BALTIMORE
18840040 METHODS OF TREATING, AMELIORATING, OR PREVENTING HEART FAILURE, AND METHODS OF PROMOTING HEART MUSCLE GROWTH Non-Final OA Yale University
18034965 METHODS OF TREATING TUMORS AND CANCERS HAVING DYSREGULATED WNT SIGNALING PATHWAYS Final Rejection ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
18852579 T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING A PIPERAZINE OR 1,4-DIAZEPANE CORE AND METHODS OF USE THEREOF Non-Final OA Praxis Precision Medicines, Inc.
18549249 TREATING CANCER IN PATIENT HAVING CO-OCCURRING GENETIC ALTERATION IN FGFR2 AND A CANCER DRIVER GENE Final Rejection TAIHO PHARMACEUTICAL CO., LTD.
18910811 PLATINUM COMPLEXES AND DEVICES Non-Final OA Universal Display Corporation
18288734 METHODS FOR TREATING AND MONITORING PARKINSON'S DISEASE Final Rejection Denali Therapeutics Inc.
18833879 PROPYLENE KETONE-CONTAINING BIOINHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF Non-Final OA JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD.
18713561 COMPOUNDS AND METHODS FOR MODULATING SPLICING Non-Final OA REMIX THERAPEUTICS INC.
18072314 HETEROCYCLIC COMPOUNDS AND USES THEREOF Non-Final OA Twelve Therapeutics, Inc.
18550488 SARS-CoV-2 inhibitors - artificial compounds Final Rejection Individual inventor

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Who Appears Before This Examiner

Top companies before this examiner

Law firms appearing most often

Frequently Asked Questions

What is examiner Dawanna Shar-Day White's allowance rate?

63.1% of resolved applications examined by Dawanna Shar-Day White were allowed (130 resolved cases), compared with 35.4% across Art Unit 1627 over the last five years.

Does an interview help with examiner Dawanna Shar-Day White?

This examiner's interview lift is +21.1 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.

How long does examiner Dawanna Shar-Day White take to allow a patent?

Applications allowed by Dawanna Shar-Day White took 1,266 days on average from filing to allowance.

Which art unit does examiner Dawanna Shar-Day White work in?

Dawanna Shar-Day White examines applications in Art Unit 1627 in Tech Center 1600 (Biotechnology & Pharmaceuticals).

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month